NOVNN Stock Chart & Stats
$2602.21
$266.51(10.71%)
At close: 4:00 PM EDT
$2602.21
$266.51(10.71%)
Day’s Range― - ―
52-Week Range$2,249.00 - $2,921.51
Previous CloseN/A
Volume1.31K
Average Volume (3M)44.00
Market Cap
$4.27T
Enterprise Value$275.93K
Total Cash (Recent Filing)$7.71B
Total Debt (Recent Filing)$49.15B
Price to Earnings (P/E)20.9
Beta0.31
Next Earnings
Oct 27, 2026EPS Estimate
38.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.59
Shares Outstanding2,034,819,500
10 Day Avg. Volume0
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,651.41Price Target Upside1.89% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)183.78
Revenue Forecast (FY)$1.19T
Bulls Say, Bears Say
Bulls Say
Diversified Growth PortfolioBroad-based growth across several priority medicines reduces reliance on any single product and supports resilience as individual brands mature. Strong expansion across oncology, immunology, cardiovascular and neuroscience franchises can sustain revenue momentum and strengthen Novartis’s market position over the coming quarters.
Strong Cash GenerationSubstantial free cash flow demonstrates that Novartis converts its pharmaceutical earnings into deployable cash. This supports continued research investment, business development, dividends and buybacks while providing capacity to absorb patent-related volatility and fund future growth initiatives.
High Pharmaceutical ProfitabilityHigh margins reflect the economic strength of Novartis’s branded, innovative-medicines model and its portfolio of differentiated products. Strong operating profitability provides room to fund R&D and launches, protect competitive advantages, and maintain cash generation even when mix or pricing pressure emerges.
Bears Say
Entresto Generic ErosionLoss of exclusivity exposes a major medicine to generic competition, creating a structural revenue headwind rather than a temporary demand fluctuation. The Entresto decline can weigh on growth and comparisons through the next several quarters, requiring newer launches to replace lost sales.
Near-term Sales And Margin PressureThe first-half deterioration shows that generic erosion and portfolio mix shifts are already affecting operating performance. Although management expects improvement in H2, lower sales and margins reduce earnings momentum and raise the execution burden on growth brands and newly launched products.
Rising LeverageHigher leverage reduces financial flexibility and makes Novartis more sensitive to earnings or cash-flow volatility. Increased debt may constrain future capital allocation and raises the importance of sustaining strong cash generation while the company funds launches, acquisitions and ongoing research.
Novartis AG News
NOVNN FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was $2249.00 and its highest was $2921.51 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is $4.27T.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Oct 27, 2026 which is in 47 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Jul 21, 2026. The company reported $40.715 earnings per share for the quarter, beating the consensus estimate of $36.627 by $4.088.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 38.06.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of $40.715 in its last earnings report, beating expectations of $36.627. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in MX:NOVNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOVNN Stock 12 Month Forecast
Average Price Target
$2,651.41
▲(1.89% Upside)
Technical Analysis
Roche Holding AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Sandoz Group Ltd
―
Galderma Group AG
―